Migraine Treatments Vary Widely for Patients with Obesity

Research Summary

A recent study published in Headache explores treatment differences in migraine patients with obesity, using data from Israel's Clalit Health Services. The research included 11,934 patients with obesity and 11,934 without, all newly diagnosed with migraine between June 2020 and June 2023. Patients with obesity were more likely to have cardiovascular and psychiatric issues. Surprisingly, these patients were more frequently prescribed migraine-specific acute medications like triptans (17% more likely) and preventive treatments such as topiramate (66% more likely), gabapentinoids (30% more likely), and duloxetine (42% more likely). This suggests that migraine patients with obesity are not undertreated but instead receive more medication.

Study Details

📄 Title: Do patients with migraine and obesity receive different treatments? Insights from real-world data.

👥 Research Team: Pardo K et al.

📚 Published In: Headache

📅 Publication Date: 2025 Dec 15

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.